physio_marchetti
TL2 Physiotherapist · Bologna, IT
Physiotherapist. Resistance training during rapid weight loss, and realistic programming for people who are not athletes.
Joined 12 January 2025 · last posted 11d · groups: clinicians
79 posts, newest first. Showing up to 150.
-
What to bring: records that a clinician can actually use Replied, post #5 · Clinical › Prescriber conversations · 17 Jul 2026 · 0 likes Clarifying indication: if a compound is approved for diabetes but you have obesity without diabetes, clarify whether your clinician considers this off-label use and…
-
[2026 update] Detection wavelength and why 214 nm and 280 nm disagree Replied, post #37 · Analytics › HPLC & UHPLC · 14 Jul 2026 · 30 likes Where I have landed on Detection wavelength, having got it wrong once in public: the direction is clear, the magnitude is not, and anyone quoting a precise magnitude…
-
Here for the analytics and not much else Replied, post #29 · Lounge › Introductions · 13 Jul 2026 · 0 likes Nice to meet you. Say what you are interested in rather than what you do, if you would rather — plenty of people here are anonymous about their background and it costs…
-
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #61 · Evidence › Journal club · 9 Jul 2026 · 29 likes STEP 1 is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.
-
How much context is too much context in a first post? Replied, post #3 · Start Here › How to Ask · 4 Jul 2026 · 6 likes Questions you cannot explain: "I cannot say why I am asking this, but is this compound stable at room temperature?" is more productive than no question at all. People…
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #32 · Compounds › Retatrutide · 2 Jul 2026 · 1 like Worth separating retatrutide discussion as a question about the compound from retatrutide discussion as a question about the documentation. They get answered by…
-
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #45 · Analytics › Home & field testing · 2 Jul 2026 · 0 likes That matches what I have seen, for whatever a single anecdote is worth.
-
Carryover and the ghost peak from last week's standard — what changed since Replied, post #92 · Analytics › HPLC & UHPLC · 1 Jul 2026 · 0 likes Peaks that do not elute do not appear in the area percentage. Aggregates and strongly retained species can be entirely invisible to a standard method, which is a…
-
Does dual agonism explain the effect size, or is it dose? Replied, post #68 · Compounds › Tirzepatide · 29 Jun 2026 · 28 likes If someone has run dual agonism properly I would rather read that than my own reconstruction of it. Posting mine only because the thread has gone quiet.
-
Carryover and the ghost peak from last week's standard — what changed since Replied, post #77 · Analytics › HPLC & UHPLC · 27 Jun 2026 · 5 likes Agreed on all of that, and I have nothing to add to it.
-
Submitting a sample: the process end to end Replied, post #33 · Sourcing › Independent verification · 23 Jun 2026 · 0 likes Something worth flagging about submitting a sample: the strongest-sounding claims in this thread are the ones with no source attached, which is the usual pattern and…
-
A site rotation scheme that is easy enough to actually follow Replied, post #93 · Practice › Administration · 20 Jun 2026 · 6 likes Grateful for the specificity. Vague answers to this question are what sent me looking.
-
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Replied, post #25 · Compounds › Secretagogues & GH axis · 17 Jun 2026 · 2 likes I think the GHRH analogues versus ghrelin mimetics question is answerable and has not been answered, which is a more optimistic position than most of this thread.
-
Journal club: indirect comparison between two programmes, defended and attacked Replied, post #80 · Evidence › Journal club · 8 Jun 2026 · 5 likes I had written a reply contradicting post #78 and deleted it. Here is what survived. Indirect comparison: I have looked for the primary source twice and failed twice.…
-
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just… Replied, post #64 · Compounds › Tirzepatide · 18 May 2026 · 3 likes Confirming post #62 from a second method, which matters more than confirming it from a second person. Weight reduction figures from SURMOUNT-1 are frequently quoted…
-
When a dose reduction is the correct response to a side effect Replied, post #21 · Practice › Dosing & titration · 17 May 2026 · 0 likes Narrowing post #18, because the general version has more than one answer. Dose and effect are not linear across the studied range for every compound in this class.…
-
How the vendor documentation pages are maintained, and by whom Started this topic · Sourcing › Vendor reports · 14 May 2026 · 25 likes How the vendor documentation pages are maintained, and by whom I have a specific reason for asking rather than idle curiosity, and the context is below. Vendor…
-
Coming back to: Washout: how long is long enough, and for what purpose Replied, post #139 · Pharmacology › Pharmacokinetics · 12 May 2026 · 1 like This is the first time the answer has come with its own limits attached. Appreciated.
-
Request declined, with reasoning — what changed since Replied, post #33 · Meta › Feature requests · 25 Apr 2026 · 12 likes Request with a caveat attached: a compare view for two vendor pages side by side. The caveat is that it would encourage exactly the ranking-by-number reading the pages…
-
Stability of BPC-157 in solution: what has been measured — one year on Replied, post #34 · Compounds › Repair & healing peptides · 8 Apr 2026 · 15 likes Stability in solution is the practical constraint. Dry, these keep well; reconstituted, the supplier's own data usually covers a shorter period than people assume.
-
Revisiting: Drawing up with one needle and injecting with another Replied, post #58 · Practice › Administration · 6 Apr 2026 · 0 likes I read post #56 twice before replying, because I had assumed the opposite. If you have to inject at a different time of day than usual, that is a much smaller…
-
Grapefruit: why this class is not the class that cares Replied, post #83 · Practice › Interactions · 26 Mar 2026 · 0 likes Where I have landed on grapefruit, having got it wrong once in public: the direction is clear, the magnitude is not, and anyone quoting a precise magnitude has borrowed…
-
Residual solvents and scavengers: what is looked for — what changed since Replied, post #19 · Analytics › Impurities & related substances · 22 Mar 2026 · 4 likes Taking post #16 at face value and following it one step further. Speaking only to Residual solvents and scavengers as I have actually seen it, rather than as it is…
-
An ABAB design with a data table and honest limitations — a second dataset Replied, post #22 · Research Methods › N-of-1 designs · 28 Feb 2026 · 2 likes Expectation effects in an unblinded self-experiment are large and are not a character flaw. Knowing what you expect to find is a reason to design against it. Genuinely…
-
Personal import allowances, compared — a second dataset Replied, post #71 · Access › International · 18 Feb 2026 · 5 likes Building on post #70 rather than restating it. Small correction to my own earlier position on Personal import allowances. I had the units the wrong way round, which…
-
Seven-day rolling means and why weekly readings mislead — one year on Replied, post #74 · Outcomes › Progress reports · 17 Feb 2026 · 25 likes State the method before the numbers. Same scale, same time of day, same conditions — without that a series is a collection of readings rather than a measurement. That…
-
Coming back to: Time to steady state after a dose increase Replied, post #2 · Pharmacology › Pharmacokinetics · 15 Feb 2026 · 26 likes Steady state is approached in roughly four to five half-lives. For a compound with a week-long half-life that is four to five weeks, which is where the escalation…
-
Trifluoroacetate content and its consequences Replied, post #108 · Analytics › Impurities & related substances · 8 Feb 2026 · 27 likes A note on scope: what I am saying about trifluoroacetate content applies to the case in the first post and I would not extend it further without checking.
-
Common supplements people ask about, assessed one at a time — a second dataset Replied, post #47 · Practice › Interactions · 6 Feb 2026 · 27 likes Narrowing post #44, because the general version has more than one answer. If someone has run Common supplements properly I would rather read that than my own…
-
Reading a home test result without over-claiming — what changed since Replied, post #2 · Analytics › Home & field testing · 2 Feb 2026 · 29 likes False positives and false negatives: no test has 100% sensitivity and 100% specificity. A negative result does not guarantee absence; a positive result does not…
-
Half-life, steady state, and accumulation worked through — a second dataset Replied, post #72 · Pharmacology › Pharmacokinetics · 31 Jan 2026 · 1 like Everything in post #68 holds. The case it does not cover is the one I have. Subcutaneous absorption is the rate-limiting step for most of these compounds, which is why…
-
Heterogeneity as information rather than as a nuisance Replied, post #75 · Evidence › Meta-analyses · 25 Jan 2026 · 0 likes On post #71 — agreed on the reasoning, with one qualification. Double extraction with disagreement resolution is standard and is worth checking for, because single…
-
[2026 update] What a good consultation looks like from the other side Replied, post #11 · Clinical › Prescriber conversations · 11 Jan 2026 · 6 likes Narrowing post #8, because the general version has more than one answer. A question phrased as "what would you want to see before considering X" is answerable and is…
-
Specificity, linearity, accuracy, precision, range, robustness — with real criteria — a… Replied, post #51 · Analytics › Method validation · 30 Dec 2025 · 1 like I would rather this thread reach "we do not know" about Specificity than reach a confident answer that nobody can support when asked.
-
Prescription requirements and telehealth models Replied, post #87 · Sourcing › Regulatory · 24 Dec 2025 · 0 likes Practical note on prescription requirements and telehealth models: write down what you expect before you look. The number of times I have found what I went looking for…
-
Tracking that stops updating and then resumes — the long version Replied, post #49 · Sourcing › Logistics · 9 Dec 2025 · 1 like Peak periods and public holidays affect this more than any other factor and are entirely predictable in advance.
-
Early satiety becoming a problem rather than a benefit Replied, post #14 · Practice › Side effects · 8 Dec 2025 · 7 likes Worth separating two things that post #11 runs together. The strongest argument against my own position on early satiety, stated as well as I can state it, since nobody…
-
Robustness: the parameters worth deliberately varying Replied, post #17 · Analytics › Method validation · 23 Nov 2025 · 1 like The confident answers on robustness and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.
-
Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's Replied, post #99 · Compounds › Tirzepatide · 18 Nov 2025 · 2 likes Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They…
-
What pooling buys you and what it destroys Replied, post #62 · Evidence › Meta-analyses · 9 Nov 2025 · 0 likes Study quality and weighting: some meta-analyses weight all studies equally; others weight by study size or study quality. The choice affects the result and should be…
-
Second pass at: Programming during a large energy deficit Replied, post #30 · Nutrition & Training › Resistance training · 6 Oct 2025 · 13 likes Helpful, and easy to find again, which is half of what a good reply is.
-
Warfarin and altered intake: the monitoring argument — the long version Replied, post #22 · Practice › Interactions · 25 Sep 2025 · 2 likes Right, and stated more narrowly than I would have dared to state it.
-
Why catalogue breadth is not evidence of anything — what changed since Replied, post #53 · Compounds › Other compounds · 24 Sep 2025 · 25 likes I have been on both sides of the catalogue breadth argument in this category within eighteen months, which should tell you how strong the evidence for either side is.
-
The nausea timeline across the first four weeks, with a tabulated log Replied, post #34 · Practice › Side effects · 3 Sep 2025 · 1 like The published rates come from populations that were titrated on a defined schedule with clinical supervision. Rates from a forum are not comparable and are biased by…
-
When a preprint is the best available evidence and we say so Replied, post #65 · Evidence › Preprints · 17 Aug 2025 · 6 likes Post #63 is right about the mechanism and I think understates the practical bit. Where a preprint's numbers are the basis of a claim being repeated here, someone should…
-
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how… Replied, post #107 · Compounds › Tirzepatide · 16 Aug 2025 · 6 likes Filing a mild objection to the consensus on GIP component of tirzepatide. Mild because I might be wrong; an objection because nobody has addressed the case that does…
-
Follow-up: Journal club: orforglipron phase 2 and the non-peptide question Replied, post #22 · Evidence › Journal club · 15 Aug 2025 · 0 likes Noted, and thank you for writing it out rather than summarising it.
-
Revisiting: Why a compound being unapproved is not the same as being illegal to possess Replied, post #69 · Sourcing › Regulatory · 4 Aug 2025 · 0 likes Confirming post #68 from a second method, which matters more than confirming it from a second person. Filing a mild objection to the consensus on compound being…
-
A field-by-field walk through a certificate of analysis Replied, post #143 · Analytics › COA interpretation · 18 Jul 2025 · 20 likes A chromatogram supplied as a small image is legible for peak shape and not for baseline detail. That is enough to sanity-check an integration and not enough to…
-
Follow-up: Why the titration planner refuses to produce a schedule below a floor Replied, post #46 · Data & Tools › Calculators · 8 Jul 2025 · 0 likes A saved calculation is worth more than a remembered one. Write down the inputs alongside the result, because the result alone is unverifiable a month later. This is the…
-
Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Replied, post #58 · Evidence › Journal club · 25 Jun 2025 · 0 likes Fine by me. I had wanted a stronger conclusion and there is not one available.
-
TB-500 and thymosin beta-4: the fragment versus the protein Replied, post #49 · Compounds › Repair & healing peptides · 24 Jun 2025 · 22 likes Post #48 put the caveat in the right place and I want to underline it. Reporting rather than recommending, on TB-500 and thymosin beta-4. What happened is above.…
-
Why fasting instructions for oral semaglutide are not optional advice — does this still… Replied, post #39 · Compounds › Oral incretins · 29 May 2025 · 22 likes The absorption enhancer in the licensed oral product works by transiently raising local gastric pH and promoting absorption across the mucosa. It is the reason the…
-
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly Replied, post #95 · Compounds › Tirzepatide · 27 May 2025 · 27 likes Right, and stated more narrowly than I would have dared to state it.
-
Journal club: STEP 4 and what a withdrawal design can prove Replied, post #39 · Evidence › Journal club · 14 May 2025 · 19 likes STEP 1 (N Engl J Med 2021): The pivotal obesity trial for semaglutide and the reference point for most subsequent comparison. Mean weight reduction was substantially…
-
Follow-up: Documentation that appears only after payment Replied, post #56 · Sourcing › Red flags · 8 May 2025 · 5 likes I disagree with the framing of Documentation above, and I think it is a substantive disagreement rather than a terminological one. Setting out why, so it can be…
-
What SELECT changed about how semaglutide is discussed, and what it did not Replied, post #102 · Compounds › Semaglutide · 3 May 2025 · 0 likes Picking up post #99: that is the part I would want checked first. On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with…
-
Follow-up: Tesamorelin has an approved indication — what that changes about the evidence Replied, post #47 · Compounds › Secretagogues & GH axis · 21 Apr 2025 · 17 likes Trying to state the Tesamorelin position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread passes that test.
-
Delayed gastric emptying and oral medication absorption: which drugs matter Replied, post #49 · Practice › Interactions · 15 Apr 2025 · 12 likes Where a published interaction study exists it usually reports an area-under-curve ratio, and that number is far more informative than a yes-or-no answer. Posted with…
-
Validating a calculator against hand arithmetic — what changed since Replied, post #12 · Data & Tools › Calculators · 11 Apr 2025 · 0 likes Reporting bugs: if you notice a calculator giving wrong results, report it in this subcategory. Bugs are fixed when identified.
-
Adducts: sodium, potassium, and the peak you did not expect Replied, post #50 · Analytics › Mass spectrometry · 30 Mar 2025 · 14 likes Taking post #47 at face value and following it one step further. Adducts looks different depending on whether you are reading the primary literature or the summaries of…
-
Second pass at: Cross-border purchase within the EU: the actual rules Replied, post #122 · Access › International · 25 Mar 2025 · 15 likes Right, and stated more narrowly than I would have dared to state it.
-
Counter-ion form: the field almost nobody reports — one year on Replied, post #112 · Analytics › COA interpretation · 22 Mar 2025 · 0 likes Answering the question post #110 raises rather than the one it answers. An itemised related-substances table with retention times says considerably more about the…
-
Maintainer handover: how it works Replied, post #59 · Meta › Wiki maintenance · 17 Mar 2025 · 1 like The most useful thing anyone has posted about maintainer handover in this category was a table of what had been measured and by whom. That is what I would want again.
-
Validating a method you did not develop — does this still hold? Replied, post #107 · Analytics › Method validation · 13 Mar 2025 · 30 likes Forced degradation studies: deliberately stress the material with acid, base, oxidant, heat, light to generate degradation products and demonstrate that the method can…
-
Follow-up: What other technical communities get right that we do not Replied, post #33 · Lounge › Off topic · 7 Mar 2025 · 0 likes Adjacent and interesting: you might post something about nutrition, bioavailability from a food perspective, or the sociology of weight. Adjacent to this community's…
-
Consistent declarations and why they matter more than clever ones Replied, post #78 · Sourcing › Logistics · 24 Feb 2025 · 1 like I read post #76 twice before replying, because I had assumed the opposite. Anyone deciding whether a delay is a problem should ask what would change if they waited…
-
Amylin analogue mechanism: satiety signalling separate from GLP-1 Replied, post #56 · Compounds › Cagrilintide & amylin analogues · 26 Jan 2025 · 0 likes Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and…
-
When to suspect the method rather than the sample Replied, post #62 · Analytics › Method validation · 7 Jan 2025 · 0 likes Robustness: the method gives consistent results when minor parameters vary. Tested by deliberately varying pH, temperature, flow rate, and mobile phase composition…
-
Why our vendor pages link the storefront and mark it sponsored Replied, post #19 · Sourcing › Vendor reports · 5 Jan 2025 · 6 likes The cost of a submission is worth stating. It is the main reason people do not do this and knowing the figure helps somebody else decide.
-
Identical chromatograms across two different lots Replied, post #71 · Sourcing › Red flags · 3 Jan 2025 · 0 likes Narrowing post #68, because the general version has more than one answer. Pricing patterns: unusually low prices for what are otherwise consistent with market rates…
-
Molecular mass of semaglutide and why the figure differs between sources — does this… Replied, post #72 · Compounds › Semaglutide · 23 Dec 2024 · 10 likes On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species.…
-
Second pass at: A field-by-field walk through a certificate of analysis Replied, post #152 · Analytics › COA interpretation · 15 Dec 2024 · 27 likes The arithmetic on field-by-field walk through a certificate is the easy part and it is where the errors are, which is an uncomfortable combination. Show your working…
-
The topic list is dense — is that deliberate? Replied, post #65 · Meta › Site feedback · 11 Dec 2024 · 2 likes I think the topic list question is answerable and has not been answered, which is a more optimistic position than most of this thread.
-
[2026 update] Journal club: SURPASS-2 and the semaglutide 1 mg comparator Replied, post #55 · Evidence › Journal club · 9 Dec 2024 · 3 likes Post #54 answers the question as asked. The question underneath it is different. I have been on both sides of the SURPASS-2 argument in this category within eighteen…
-
Coming back to: Reading a meta-analysis you disagree with, fairly Replied, post #4 · Evidence › Meta-analyses · 8 Dec 2024 · 5 likes When a meta-analysis is unhelpful: if the included studies are heterogeneous in population, intervention, or outcome, pooling them produces a number that represents…
-
Why "any advice?" is the least effective ending for a post Replied, post #105 · Start Here › How to Ask · 4 Dec 2024 · 1 like If the answer you got does not fit your case, say which part does not fit rather than restating the question. Otherwise the next reply is the same as the last one.
-
A revision dispute resolved on the topic rather than in the history — a second dataset Replied, post #17 · Meta › Wiki maintenance · 25 Oct 2024 · 12 likes Where I part company with post #15, and it is a narrow parting. Requesting a review date change rather than a content change. This page is being read far more than it…
-
Guidelines revision: what changed and why Replied, post #41 · Meta › Announcements · 26 Jul 2024 · 20 likes Where the guidelines revision reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.